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Objective To compare two immunoassays for detection of toxins produced in vitro by
isolates of Clostridium difficile with the standard tissue culture assay, to help in the
diagnosis of C. difficile-associated diarrhoea.
Methods Toxin production was investigated in 42 strains of C. difficile of various
serotypes, ribotypes and S-protein types. These included strains from our laboratory
collection, strains freshly isolated from stool specimens of patients suspected of suffering
from C. difficile-associated disease or of carrying it asymptomatically, and one reference
strain (NCTC 11223). Toxin was assayed by (i) a rapid slide immunoassay (C. difficile toxin
A test, Clearview, Oxoid), (ii) an enzyme-linked microplate immunoassay (C. difficile
toxin A/B test, Techlab), and (iii) a tissue culture assay. The rapid slide assay and the
enzyme immunoassay were performed according to the manufacturers’ recommenda-
tions. The tissue culture assay was performed using Vero cells.
Results Thirty of the 42 strains (71%) were shown to be positive for toxin A by the slide
immunoassay and 34 of the strains (81%) were found to be toxin A/B producers by the
enzyme immunoassay. The same 34 strains that were positive in the enzyme immu-
noassay also produced toxin B (cytotoxin) in the tissue culture assay. The sensitivity,
specificity, and positive and negative predictive values for the rapid slide immunoassay
method were calculated to be 88.2%, 100.0%, 100.0% and 66.7%, respectively, when
compared to tissue culture assay results as the reference method. These values for the
enzyme immunoassay method were all 100.0%. In this study eight strains were found to
be non-toxin-producing by all methods. It is possible that there were four strains that only
produced toxin B (A– Bþ), and were missed by the rapid A-only assay.
Conclusions We can recommend the use of the Techlab AþB enzyme immunoassay for
the detection of toxin production by C. difficile strains because of its high sensitivity and
specificity, its ease of use, and its capability of detecting both A- and B-type toxins.
Keywords Clostridium difficile, toxin A, toxin B, immunoassay, antibiotic-associated
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I N T R O D U C T I O N
Until the mid-1970s, the clinical importance of
Clostridium difficile was not understood. However,
it is now clearly recognized that this organism is
responsible for antibiotic-associated gastrointest-
inal diseases ranging from benign diarrhoea to
life-threatening pseudomembranous colitis [1,2].
There are a number of virulence factors associated
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with this organism. Toxins A and B are considered
the most important but there are also various
extracellular enzymes and an ADP-ribosylating
toxin, and even spore formation is an important
attribute [1]. S-layer proteins, which vary consid-
erably between strains, both in molecular mass
and immunogenic reactivity, might have a role
in virulence by promoting adherence and coloni-
zation or by evasion of the immune system [3,4].
The pathogenicity of C. difficile is clearly asso-
ciated with the production of the two exotoxins,
toxin A and toxin B, two of the largest bacterial
toxins known, with molecular weights of 308 000
and 270 000, respectively. Toxin A is primarily an
enterotoxin and causes hemorrhage and fluid
secretion, and is also chemotactic for neutrophils.
It elicits the release of cytokines that play impor-
tant roles in its pathogenesis. Both toxins enter the
cell primarily by receptor-mediated endocytosis.
Toxin B is lethal and very cytotoxic for most cell
lines, while toxin A has some cytotoxic activity but
much less than toxin B. The toxins are believed to
exert an additive effect in vivo causing destruction
of the cellular cytoskeleton by inducing depoly-
merization of actin. For a recent review on the
actions of the toxins, and other virulence factors of
C. difficile, see Poxton et al. [5].
C. difficile-associated diarrhea is an emerging
nosocomial problem in many countries [6,7]. Evi-
dence suggests that the nosocomial spread of this
organism can occur by direct patient to patient
contact, by transmission to patients from the hands
of the hospital personnel, or by acquisition from
the environment [8].
There is still debate as to whether culture or
direct detection of toxin in stool specimens is the
preferred method for diagnosis. Culture is
obviously important for epidemiological studies,
while toxin detection in stools can give a rapid indi-
cation that the patient is being exposed to biolo-
gically active toxin. Many studies have compared
various commercially available immunoassays for
direct detection of toxin. However, if culture is
considered important then it is necessary to be able
to demonstrate toxin production by the isolates.
The aim of our study was to compare three simple
methods for detection of toxin (toxin A-only
immunoassay, a toxin AþB immunoassay and
the tissue culture) from a wide range of isolates
of C. difficile. These 42 strains varied in cell surface
phenotype (different serotypes and S-protein
types), genotype (ribotype), and came from a wide
range of patients and geographical origins. It is
important to be able to detect the production of
toxins in isolates of C. difficile to help in the diag-
nosis of C. difficile-associated disease.
M A T E R I A L S A N D M E T H O D S
Bacterial strains
Forty-two C. difficile strains of various ‘Delme´e’
serotypes (A, B, C, D, F, G, H, I, K and X), ‘Cardiff’
ribotypes (10, 23, 26, 56 and 106), ‘Edinburgh’ S-
protein types (5336, 5242, 5144 and 5941; see [4] for
description of ‘S-type’), and a selection of unchar-
acterized isolates from patients with symptoms
and from symptomless babies were used in the
study. These included strains from our laboratory
collection, strains freshly isolated from the stool
specimens of patients suspected of suffering from
C. difficile-associated disease (CDAD), symptom-
less patients and one NCTC strain (NCTC 11223).
Culturing for toxin testing
The strains were inoculated into brain heart infu-
sion, proteose peptone medium [9] and incubated
under anaerobic conditions at 37 8C for 5 days.
Toxin was measured in supernates that were
obtained after cultures had been centrifuged at
3000 g for 20 min.
Toxin tests
The toxin production by the strains was investi-
gated by (i) a rapid slide immunoassay (C. difficile
toxin A test, ClearviewTM Oxoid, Basingstoke,
UK), (ii) a microplate enzyme immunoassay
(EIA; C. difficile toxin AþB, Techlab, Blacksburg,
VA, USA), and (iii) a tissue culture assay (see
below). The rapid slide immunoassay and the
microplate assay were both performed according
to the manufacturers’ recommendations.
For the rapid slide immunoassay 100mL culture
supernatant was added to 1 mL sample diluent and
vortexed for 10–15 s. This sample (125mL) was ino-
culated to the test unit. Blue latex particles, which
had been sensitized with antibody specific to C.
difficile toxin A, bound to toxin A in the sample
and this complex was trapped by antibody to toxin
A, forminga visibleblue line.Theresultsof therapid
slide assay were read 30 min after the application of
the sample to the test unit. A blue line in the control
and result windows indicated a positive result.
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For the EIA, 50 mL of the culture supernatant
were added to 200 mL of the specimen diluent and
vortexed for 10 s. After adding one drop of con-
jugate to the wells, two drops of diluted sample
were inoculated. One negative and one positive
control well were included for each plate. The
plate was incubated in a shaker at 37 8C for
50 min. After washing, one drop of substrate A
and one of substrate B were added to the wells.
After 10 min one drop of stopping solution was
added. The results of the EIA were read visually
and spectrophotometrically at a dual wavelength
450/620 nm and the wells with an optical density
(OD) <0.080 were interpreted as negative while
those with an OD of 0.080 were considered
positive. The assay took approximately 1.5 h.
Tissue culture assay
For the tissue culture assay Vero cells were cul-
tured in Eagle’s minimal essential medium (alpha
modification: Sigma, St Louis, MO, USA) supple-
mented with fetal calf serum (7%), L-glutamine
(2 mM), penicillin (200 units/mL) and streptomy-
cin (200 mg/mL) at 37 8C in 5% CO2. The cells were
grown to confluent monolayers in 75 cm2 flasks,
counted with Trypan blue in an improved Neu-
bauer counting chamber and resuspended in fresh
medium at a concentration of 105 cells/mL. This
was used to seed 96-well microtitre plates, adding
200 mL volumes to each well of a 24-well plate.
Plates were incubated for 20–24 h before the inocu-
lation of the culture supernatants. Serial dilutions
of the C. difficile culture supernatants were made in
sterile saline and 20 mL of these diluted samples
was inoculated into the wells. The plates were
incubated at 37 8C in 5% CO2 and assay results
were determined for typical changes after 24 and
48 h according to a scale from 0 to 4þ [4þ being the
titre showing a 95–100% cytopathic effect (CPE)
compared to the control wells]. The cytotoxic titres
were expressed as the highest dilution exhibiting
>50% (3þ) CPE.
R E S U L T S
Thirty of the 42 strains (71%) were shown to be
positive for toxin A by the slide immunoassay and
34 of the strains (81%) were found to be toxin A/B-
producing by the microplate assay. The visual and
spectrophotometric dual wavelength results gave
exactly the same result.
The same 34 strains that were positive in the
EIA also produced toxin B (cytotoxin) in the tissue
culture assay. The distribution of the tissue cul-
ture results according to the titres is shown in
Table 1.
The sensitivity, specificity and positive and
negative predictive values (PPV, NPV) for both
methods, when compared to tissue culture assay
results as the reference method, are shown in
Table 2. The agreements between rapid immu-
Table 1 The distribution of the
tissue culture results according to



















24 h 3 (8.8) 4 (11.8) 8 (23.5) 14 (41.2) 4 (11.8) 1 (2.9) –
48 h 2 (5.9) 3 (8.8) 7 (20.6) 14 (41.2) 5 (14.7) 2 (5.9) 1 (2.9)
Table 2 The sensitivity, specificity,
positive and negative predictive









(95% CI) (71.6, 96.2) (87.4, 100.0)
Specificity 100.0% 100.0%
(95% CI) (59.8, 100.0) (59.8, 100.0)
Positive predictive value 100.0% 100.0%
(95% CI) (85.9, 100.0) (87.4, 100.0)
Negative predictive value 66.7% 100.0%
(95% CI) (35.4, 88.7) (59.8, 100.0)
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noassay and tissue culture results and between
EIA and tissue culture results, were 90.5% and
100%.
In this study eight strains (serotypes D, I, X, A7
and A10; ribotype 10, S type 5144/ribotype 26 and
an uncharacterized isolate from a symptomatic
patient) were found to be non-toxin-producing
by all methods. It is possible that there were four
strains (serotypes K, A8, A9 and an uncharacter-
ized strain isolated from a symptomless baby) that
only produced toxin B (A– Bþ), and were missed by
the rapid A-only assay.
D I S C U S S I O N
The widespread use of broad-spectrum antibiotics
is causing an increasing incidence of pseudomem-
branous colitis and antibiotic-associated diarrhoea
[10]. Clostridium difficile causes disease in hospita-
lized adults, primarily the elderly and those
receiving antibiotics such as clindamycin, ampi-
cillin, or oral cephalosporins [11]. The presence of
diarrhoea and a history of recent antimicrobial
therapy are only suggestive of CDAD; laboratory
tests are necessary for the confirmation of the
diagnosis [10].
Detection of toxin in the stool of a symptomatic
patient is one of the most accurate methods for the
diagnosis of these infections. Although important
for epidemiology, the detection of just the organ-
ism may have limited value because the asympto-
matic carriage rate may be high in hospitalized
patients receiving antibiotics. Organisms that do
not produce toxin are thought to be avirulent [12],
and thus interpretation of a positive culture result
alone is not possible. Toxin production by isolates
is therefore a useful piece of extra evidence when
attempting to make a definite diagnosis based on
culture alone.
The detection of toxin B by the tissue culture
assay is considered to be the standard [13]. How-
ever, tissue culture techniques are not routinely
available in most diagnostic laboratories. The tech-
nique may require an incubation period of up to
24 h (although strong positives can be seen after a
few hours) and there are problems with the stan-
dardization of the method. The laboratory proto-
cols vary in the dilutions and cell lines used, and
in the interpretation of the assay endpoint [14].
Some authors accept a 50% CPE as a positive
result, however, some consider a >90% CPE as
the endpoint.
Yolken et al. [15] first developed and evaluated
an EIA for the detection of C. difficile toxin in 1981.
After this attempt, further developments have
continued and a number of commercial diagnostic
kits are now available for the detection of either
toxin A or both toxins. In this study of strains in
pure culture the tissue culture cytotoxicity assay
was compared with two of these tests (a slide
immunoassay for toxin A only and a microplate
immunoassay for toxins A and B). The tests we
used to detect the toxins from the culture super-
natants of the isolated strains were found to react
in the same way when detecting toxin from speci-
mens (unpublished data).
The principle of the microplate immunoassay is
based on a monoclonal antibody to toxin A and the
antigen–antibody complex is visualized by a pre-
cipitate, which is formed by blue latex coated with
antibody. The sensitivity, specificity, PPV and NPV
obtained for the toxin A test were 88.2%, 100.0%,
100.0%, 66.7%, respectively. Bentley et al. [16] used
this test to detect toxin A in fecal specimens and
reported the sensitivity and specificity values as
83.1% and 96.9%, respectively. Vanpoucke et al.
[17] used the same test and found the sensitivity,
specificity, PPV and NPV to be 89%, 83%, 71%,
94%, respectively, for the detection of toxin in stool
samples. Our rates on pure cultures are concor-
dant with the results of these studies, and it seems
reasonable to use this test for the detection of toxin
both in stool specimens and C. difficile culture
supernatants. It has the advantage of being rapid
(the result is ready after 30 min), extremely easy
and one is able to work with one specimen at a
time instead of collecting samples. The main dis-
advantage is that it will not detect toxin B pro-
duced by A– Bþ strains. However, the occurrence
of this phenotype is uncommon and localized.
We also used the toxin AþB EIA test for the
detection of both toxins. In our study the sensitiv-
ity, specificity, PPV and NPV were found to be
100.0%. In one multicenter study, this kit was used
to detect the toxins in 1152 fecal specimens and
the values obtained for the sensitivity ranged
between 83.3 and 96.0%, for the specificity between
99.3 and 100% and for NPV between 90.0 and
99.5%. They found PPV to be 100% and the corre-
lation as 94.9–99.5% when compared with the
tissue culture assay [18]. Aldeen et al. [19] com-
pared the same toxin AþB test to cell culture
cytotoxin assay in 1109 diarrhoeal stool samples.
They got the sensitivity and specificity as 94.3%,
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99.3%, initially. However, after resolution of six
discrepancies, the detected sensitivity, specificity,
PPV and NPV were 94.5%, 100%, 100% and 98.8%,
respectively. The agreement between toxin AþB
and tissue culture assay was 98.5%. Our results for
pure cultures are in parallel with the above fecal
toxin results. This test combines the advantages of
an EIA method, such as rapidity, ease of use and
sensitivity, with the capability of detecting both
toxins. Also, EIAs have objective endpoints deter-
mined with an EIA reader. De Girolami et al. [8]
compared visual and spectrophotometric readings
and have reported good correlations. Our results
are parallel to this finding. The reported sensitivity
and specificity values for other available commer-
cial EIA kits which can detect toxins A and B were
between 79.6 and 96.2%, 93.5 and 100%, respec-
tively, and PPV and NPV were between 86.7
and 100% and 95.7 and 99%, respectively [14,18,
20,21]. These results are similar to, or a little
lower than, those obtained for the Techlab A/B
test.
Four of our strains appear to be toxin A– Bþ
strains which were negative in toxin A EIA but
positive in the toxin A/B test. It is possible that the
sensitivity levels of the toxin A test we used may
be low and the production of toxin A is missed. On
the other hand, they might be true toxin A– Bþ
strains that could have caused CDAD in the
patients. Lyerly et al. [18] mentioned the presence
of a toxin A– Bþ isolate from a patient with a
clinical history consistent with C. difficile disease.
In recent years toxin A– Bþ strains have been
described in symptomatic adults in Japan and
the USA [22,23]. Alfa et al. [24] reported that the
toxin A– Bþ strain was responsible for a nosoco-
mial outbreak of CDAD. Brazier et al. [25] also
reported the same phenotype C. difficile strains
from symptomatic patients. It has been suggested
that these strains might have caused disease due to
a more active toxin B [18]. Another group reported
that it was possible either that toxin B alone was
capable of causing diarrhoea or that the strain
contained other factors capable of causing disease.
Lyerly et al. [18] also found that two serogroup
type F strains showed toxin A– Bþ phenotype in
their study. This was in agreement with the find-
ings of Depitre et al. [26]. The ribotypes of A– Bþ
strains, which were reported by Brazier et al. [25],
belonged to ribotype 17. Our apparent A– Bþ
strains belonged to serogroups A and K (K, A8,
A9). We also had a strain which belonged to
serogroup F which was found to produce both
A and B toxins.
Eight of the isolates were shown to be non-toxin-
producers. This reflects the fact that there are non-
toxigenic C. difficile strains which exist in the gas-
trointestinal tracts of hospitalized patients as nor-
mal colonizers. It is possible, but so far not proven,
that non-toxigenic strains may cause disease
depending on the predisposing factors of the host
and the virulence of these strains. In other studies
it is well recognized that a proportion of strains
isolated from patients whose clinical course was
consistent with C. difficile-associated disease were
found to be non-producers of toxin, e.g. 3% (two of
63) in the study by Clabots et al. [27].
From the result of our study we can recommend
the use of the Techlab toxin A/B enzyme immu-
noassay for the detection of toxin production by C.
difficile isolates because of its high sensitivity, spe-
cificity, ease of use and its capability of detecting
both A- and B-type toxins. However, the Oxoid,
ClearviewTM system is so easy to use, and as it is
designed for single samples, its usefulness should
not be overlooked, especially if there is no history
of Toxin A– Bþ strains in the locality. It is recom-
mended, however, that isolates of C. difficile are
regularly monitored to see which toxins they are
producing.
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